“Now, we're waiting for some more clinical data early next year, but I think it's within our reach. If we decide to do, to start the pivotal study next year to do it with an once a day molecule.”

In context

“xpected soon, how should we expect Pfizer to share those results? And then, with regard to the once daily formulation that you just mentioned, Mikael, will that be ready for the Phase 3 start assuming that the company moves to start Phase 3 shortly after the Phase 2b results are generated? Albert Bourla: The first question, given the importance [indiscernible]. But with a press release, we've made them publicly available. Now, Mikael, you want to take the second part of the question of David? Mikael Dolsten: Yeah, I can first echo what Albert and I said, we look forward with enthusiasm to get the danuglipron obesity data later this year. And of course, as Albert said, pending totality of reviewing everything we have, we have made a lot of progress and been able to accelerate the QD danu. Now, we're waiting for some more clinical data early next year, but I think it's within our reach. If we decide to do, to start the pivotal study next year to do it with an once a day molecule. Operator: Next, we have Chris Schott with J.P. Morgan. Chris Schott: Just two for me here. First, can you just comment a little bit more on what we're seeing with Nurtec and the ramp relative to your expectations? And maybe just as part of that, just any color on pricing we're seeing within the market today and how we should think about that going forward. And then my second question was on 2024. I know you're not giving guidance today. But as you look at where consensus has kind of shaken out post the COVID and cost restructuring updates, and if the earnings are in kind of low $3 range at this point, I guess just are there any directional kind of pushes or pulls in the numbers that you feel the Street isn't capturing properly and should be kind of thinking about before we get your kind”